Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trialRaphael J. Landovitz, Beatriz Grinsztejn, Mark A. Marzinke et al.|The Lancet HIV|2023Cited by 70
Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure ProphylaxisRaphael J. Landovitz, Susan H. Eshleman, Sinéad Delany‐Moretlwe et al.|New England Journal of Medicine|2024Cited by 37
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trialMark A. Marzinke, Sybil Hosek, Brett Hanscom et al.|The Lancet HIV|2023Cited by 14
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trialPaul A. Richardson, Trần Việt Hà, Beatriz Grinsztejn et al.|UNC Libraries|2025Cited by 1
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trialAdeola Adeyeye, Zhe Wang, Beatriz Grinsztejn et al.|UNC Libraries|2025Cited by 0